Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution

Sao Paulo Medical Journal

Volumn 126, Issue 1, 2008, Pages 52-57

  Linardi, Camila da Cruz Gouvia ^a   Pracchia, Luís Fernando ^a   Buccheri, Valeria ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Brazil; Polycythemia vero; Survival; Thrombosis; Treatment outcome

Indexed keywords

ACETYLSALICYLIC ACID; BUSULFAN; HEMOGLOBIN; HYDROXYUREA; INTERFERON; PHOSPHORUS 32;

ACUTE LEUKEMIA; ADULT; ARTICLE; BRAZIL; DEMOGRAPHY; EXPERIENCE; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; OVERALL SURVIVAL; PHLEBOTOMY; POLYCYTHEMIA VERA; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOSIS; WORLD HEALTH ORGANIZATION;

EID: 44649158543     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802008000100010     Document Type: Article

References (17)

1. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12(4):339-51.
2. Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Frandrin G. Polycythemia vera. In: Jaffe ES, Harris NL, Stein H, Vadiman JW, editors. World Health Organnation (WMO) Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. p. 32-4.
3. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132-43.
4. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-70.
5. Berk PD, Goldberg JD, Silverstein MN, et al. Increase incidence of acute leukemia in polycythemia vera associated with chlorambucil theraphy. N Engl J Med. 1981;304(8):441-7.
6. Gilbert HS. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Semin Hematol. 1999;36(1 Suppl 2):19-22.
7. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34(1):17-23.
8. Passamonti F, Rumi E, Pungolino, E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med, 2004; 117(10):755-61.
9. Spivak JL. The optimal management of polycythaemia vera. Br J Hematol. 2002;116(2):243-54.
10. Recommended methods for measurement of red-cell and plasma volume: International Committee for Standardization in Haematology. J Nucl Med. 1980;21(8):793-800.
11. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of parients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-32.
12. Green AR, Vassiliou GS, Curtin N, Campbell PJ. Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J, 2004;5(Suppl 3):S126-32.
13. Bench AJ, Pahl HL. Chromosomal abnormalities and molecular markers in myeloproliferative disorders. Semin Hematol. 2005;42(4):196-205.
14. Najean Y, Rain JD, Dresch C, et al. Risk of leukemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythermias". Leuk Lymphoma. 1996;22(Suppl 1):111-9.
15. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, editors. Polycythemia vera and myeloproliferative disorders. Philadelphia: WB Saunders; 1995. p. 166-94.
16. andersson B, Löfvenberg E, Westin J. Management of patients with polycthaemia vera: results of a survey among Swedish haematologists. Eur J Haematol. 2005;74(6):489-95.
17. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61.